Abstract

This comprehensive review outlines the regulatory pathways for new drug approval across major jurisdictions including FDA, EMA, and WHO. The paper discusses preclinical requirements, clinical trial phases, and post-approval obligations for pharmaceutical manufacturers.

---

References

1. Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of Pharmaceutical Excipients. 8th ed. London: Pharmaceutical Press; 2017.

2. Katdare A, Chaubal MV. Excipient functionality and innovation in pharmaceutical formulation. J Pharm Sci. 2006;95(4):821–832.

3. Thoorens G, Krier F, Leclercq B, Carlin B, Evrard B. Microcrystalline cellulose, a direct compression binder in pharmaceutical formulations—A review. Int J Pharm. 2014;473(1–2):64–72.

4. Williams RO, Watts AB, Miller DA. Formulating Poorly Water Soluble Drugs. 2nd ed. New York: Springer; 2016.

5. Goole J, Amighi K. New trends in pharmaceutical excipients for oral drug delivery. Int J Pharm. 2014;466(1–2):45–52.

6. Pifferi G, Restani P. The safety of pharmaceutical excipients. Farmaco. 2003;58(8):541–550.

7. Van der Merwe SM, Grobler AF, Steenekamp JH. Functional excipients in solid dosage forms: Applications and future perspectives. Drug Dev Ind Pharm. 2020;46(5):689–701.